Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Synthis LLC (AKA: Synthis Therapeutics Inc)
Profile last edited on: 7/17/2023      CAGE: 7NWT8      UEI: KC6RHFHRQAN6

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2014
First Award
2018
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

222 Broadway 19th
New York, NY 10038
Location: Single
Congr. District: 10
County: New York

Public Profile

Synthis, LLC is an early stage biotech company developing a novel immuno-oncology (IO) therapeutic to treat metastatic melanoma patients. The firm's therapeutic reserves immune suppression in metastatic melanoma patients who have failed immune checkpoint blockade.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$599,921
Phase II Dollars
$210,000
Total Awarded
$809,921

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 1 NIH $299,900
Project Title: Development of a targeted TGF-b therapeutic that selectively blocks lung fibrosis in idiopathic pulmonary fibrosis (IPF) patients
2020 2 NIH $566,045
Project Title: Development of a Novel Checkpoint Inhibitor-TGF Beta Combination Therapy to Reverse Immune Suppression and Increase Survival Rates in Advanced Colorectal Cancer Patients
2018 1 NIH $299,946
Project Title: Development of a T Cell-Targeted TGF-B Antagonist That Reverses Immune Suppression in Melanoma Patients

Key People / Management

  Dori A Thomas-Karyat -- CEO and Co-founder

  Mary Howard -- Executive Director

Company News

There are no news available.